The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…


Gilenya-maker Novartis features more MS patients in new online dictionary tools

Patient requests buoy oral meds from Biogen, Novartis in crowded MS market

Tecfidera, Gilenya and Aubagio's 3-way battle for MS share is about to heat up

Novartis could snag a blockbuster MS market all for itself, just in time to fight Gilenya generics